CD 68-positive tumor-associated macrophages predicts the survival of patients with stage I colorectal cancer

Xiaomei Liu,Heng Liu,Caijun Yuan,Yinxu Zhang,Yu Wang,Shuding Hu,Lei Liu,Ying Wang
2016-01-01
Abstract:Current risk stratification for patients with stage I colorectal cancer is imperfect. The aim of this study is to determine whether CD68(+) tumor-associated macrophages (TAMs) is a predictor of the outcomes in patients with stage I colorectal cancer that undergo curative surgery. One hundred eighty-nine patients with stage I colorectal cancer that underwent surgical resection between August 2005 and December 2009 were retrospectively reviewed. TAMs were detected based on immunohistochemical staining of CD68. The optimum thresholds for CD68 expression was based on the maximal 2 value of the log-rank test for disease free survival (DFS). 5-year DFS and cause-specific survival (CSS) were compared between patients with low CD68(+) TAMs and those with high CD68(+) TAMs. The 5-year DFS and CSS were lower in patients with high CD68(+) TAMs than in those with low CD68(+) TAMs (87.6% vs. 92.5%, P=0.008; 90.1% vs. 94.2%, P=0.011). Cox multivariate analysis demonstrated that CD68(+) TAMs were independently associated with DFS (HR, 4.308; 95% CI, 1.296-17.524; P=0.008) and CSS (HR, 5.294; 95% CI, 1.021-35.437; P=0.012) in patients with stage I colorectal cancer. In conclusion, CD68(+) TAMs in tumor tissue is a prognostic factor predicting DFS and CSS in patients with stage I colorectal cancer that underwent curative surgery.
What problem does this paper attempt to address?